Saturday 17 October 2026
Export CASIF’s income statement to Excel — free account
CASI Pharmaceuticals Inc.
CASIF Healthcare Biotechnology
CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024. In the quarter to December 2025, revenue fell 45.9%, EPS grew 54.4%, free cash flow fell 23,251.7% and total debt rose 6.97%, each against the same quarter a year earlier.
0.10
0.00
0.00%
Follow CASIF
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
0.58 | 0.99 | 0.76 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(0.63) | (0.91) | (0.76) | — | |
P/B ratio |
0.00 | 0.00 | 0.00 | — | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | |
EV/Sales |
1.56 | 2.23 | 2.54 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(0.90) | (1.10) | (0.76) | — | |
EV/FCF |
(0.88) | (1.06) | (0.75) | — | |
Quick Ratio |
0.32 | 0.19 | 0.20 | 0.11 | |
Current Ratio |
0.48 | 0.30 | 0.27 | 0.15 | |
Net Debt/EBITDA |
(1.08) | (1.33) | (1.67) | 0.00 | |
Debt/Assets |
60.04% | 77.08% | 91.36% | 93.91% | |
Debt/Equity |
(0.92) | (0.66) | (0.63) | (0.34) | |
Asset Turnover |
0.77 | 0.61 | 0.52 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 1.59 | — | |
Capex/Depreciation |
— | — | (0.02) | — | |
Interest Coverage |
(45.59) | (54.75) | (52.28) | — | |
Research and Development Expense of Revenue |
41.29% | 45.95% | 17.10% | — | |
Selling, General and Administrative Expense of Revenue |
264.53% | 310.15% | 195.40% | — | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 41.35% | — | |
Graham Net Nets |
(1.82) | (1.54) | (3.14) | — | |
Graham Number |
9.23 | 10.98 | 10.80 | — | |
Earnings Yield |
(244.92%) | (181.33%) | (303.53%) | — | |
Free Cash Flow Yield |
(307.66%) | (211.30%) | (447.18%) | — | |
Revenue per Share |
0.27 | 0.19 | 0.39 | — | |
Operating CF per Share |
0.00 | 0.00 | (1.12) | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | (1.12) | — | |
Cash per Share |
0.44 | 0.29 | 0.30 | 0.00 | |
Shareholders Equity per Share |
(1.31) | (1.78) | (2.01) | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.31) | (1.78) | (2.01) | 0.00 | |
Free Cash Flow |
— | — | (20.78) | — | |
Working Capital |
(19.57) | (27.51) | (36.21) | (56.59) | |
Capital Expenditures |
— | — | (0.03) | — | |
Net Current Asset Value |
(33.35) | (41.14) | (49.47) | (69.31) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
6.55 | 6.88 | 9.72 | 5.52 | |
Average Payables |
0.80 | 1.16 | 1.89 | 1.13 | |
Average Inventory |
9.01 | 7.77 | 3.43 | 3.00 | |
Average Assets |
41.24 | 44.04 | 39.66 | 30.94 | |
Average Common Equity |
(5.64) | (7.37) | (17.72) | (33.17) |
Columns are period end dates